Investors
Press Releases 2009
- 11/17/2009
IntelGenx Achieves Positive Bioequivalence Results With Novel Anti-Migraine Film
- 11/10/2009
IntelGenx Reports Results For the Third Quarter and Nine Months Ended September 30, 2009
- 10/06/2009
IntelGenx Determines Exercise Price of Stock Options to IR Firm
- 10/01/2009
IntelGenx Strengthens Investor Relations Activities
- 09/04/2009
IntelGenx Technologies Corp. Completes Additional Private Placement
- 08/31/2009
IntelGenx Technologies Corp. Announces Shareholder Call
- 08/21/2009
IntelGenx Corp. Comments on CPI-300 Patent Infringement Complaint
- 08/14/2009
IntelGenx Reports Results for the Second Quarter and Six Months Ended June 30, 2009
- 07/29/2009
IntelGenx Technologies Corp. Files Preliminary Short Form Prospectus; IntelGenx Completes Additional Private Placement
- 07/14/2009
IntelGenx Technologies Corp. Announces Closing of Private Placement
- 06/23/2009
IntelGenx Corp. Announces FDA Acceptance for Filing of NDA for CPI-300 Antidepressant
- 05/19/2009
IntelGenx Corp. and Circ Pharma to Commence Phase 1 Proof-of-Concept Study of CRES Pravastatin, a Novel Low Dose Formulation Containing Pravastatin for the Treatment of Hyperlipidemia
- 05/13/2009
IntelGenx Reports Results for the First Quarter of 2009
- 04/20/2009
Positive Bioequivalence Results for IntelGenx Developed Product
- 04/15/2009
IntelGenx Announces Appointment of New Director
- 04/14/2009
Cannasat and IntelGenx Announce Positive Phase 1(b) Results Improved buccal tablet outperforms oral dronabinol
- 04/07/2009
IntelGenx Corp. and Cary Pharmaceuticals file NDA for CPI-300 antidepressant
- 03/25/2009
IntelGenx Technologies Corp. Announces 2008 Annual Financial Results
- 01/28/2009
Cannasat Therapeutics and IntelGenx Corp. Reach Key Milestone
- 01/19/2009
IntelGenx Corp. and Circ Pharma Ltd announced today a partnership to develop and commercialise a novel drug for the treatment of hyperlipidemia.